| Price and Chart delayed at least 15 mintues. |
|
Price
$ 24.26
|
Change
0.00
|
|
Open
0.00
|
% Change
0.0%
|
|
Prev Close
24.26
|
Volume
NA
|
|
Market Value
7 bil
|
P/E Ratio
9.6
|
|
Bid
0.00
|
EPS
2.52
|
|
Ask
0.00
|
Dividend
0.00
|
|
High
0.00
|
Yield
0.0
|
|
Low
0.00
|
Shares Out
302 mil
|
|
52wk High
39.02
|
52wk Low
18.37
|
|
Industry: Drug Manufacturers - Other
|
|
Sector: Healthcare
|
FRX Profile
The Company and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical drug products which require a physician's prescription.
Forest Laboratories, Inc.
909 Third Avenue
New York, NY 10022-4731
Phone: (212) 421-7850
Fax: (212) 750-9152
Web Site: www.frx.com
FRX Wires Headlines
|
|
| 06.19.09 |
|
UPDATE 1-Forest pneumonia drug achieves goal in 2 trials
|
|
| 06.19.09 |
|
Forest Labs antibiotic meets pneumonia study goals
|
|
| 06.19.09 |
|
BRIEF-Forest Laboratories says Ceftaroline meets primary objective
|
|
| 06.12.09 |
|
Lundbeck sees U.S. franchise revs of $500 mln in 2011
|
More FRX From Wires Headlines >
Forbes.com on FRX RSS
No news found in the past 30 days.FRX Press Releases
|
|
| 06.22.09 |
|
The Microcap Underground on Stocks to Watch: Oncothyreon Inc, Forest Labs, and Johnson & Johnson |
|
| 06.22.09 |
|
Beacon Equity Research on Stocks to Watch: Forest Labs, Harris, Philip Morris, IAMGOLD, Steel... |
|
| 06.19.09 |
|
Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of... |
More FRX Press Releases >
FRX Ratios & Returns
| Price-to-sales |
1.9 |
| Return on Equity |
18.7 |
| Operating Margin |
25.7 |
| Profit Margin |
20.0% |
More FRX Ratios & Returns >
FRX Financials
| Sales |
$3.845054 bil |
| Profits |
$0.767743 bil |
| Assets |
$5.196808 bil |
| Employees |
5225.0 |
|
|
|
Forest Labs is ranked # 1053 on the 2009 Forbes 2000 List
|
|
Thomson / IBES Earnings Estimates on FRX
Accounting Risk
Buy/Hold/Sell Analysis
Forbes Investment Guru Commentary on FRX
RSS News Feed on FRX
|
A D V E R T I S E M E N T
|